Welcome to our dedicated page for Collegium Pharmaceutical news (Ticker: COLL), a resource for investors and traders seeking the latest updates and insights on Collegium Pharmaceutical stock.
News about Collegium Pharmaceutical, Inc. (Nasdaq: COLL) focuses on its activities as a biopharmaceutical company with a portfolio spanning responsible pain management and neuropsychiatry. The company regularly issues press releases on product-related research, financial performance, capital structure, and corporate initiatives, providing investors and healthcare professionals with insight into its operations.
A major theme in Collegium’s news flow is the development and commercialization of JORNAY PM, a central nervous system stimulant indicated for the treatment of ADHD in people 6 years of age and older. The company highlights real-world data on JORNAY PM at scientific meetings such as the American Professional Society of ADHD and Related Disorders (APSARD), the American Academy of Child & Adolescent Psychiatry, and the Neuroscience Education Institute conferences. Releases describe poster presentations on dosing, comparative outcomes versus other ADHD treatments, and changes in functioning and psychiatric symptoms in various patient groups.
Collegium also issues news on its pain portfolio, including BELBUCA and XTAMPZA ER. At events like PAINWeek, the company presents multiple posters that examine treatment characteristics, safety, economic burden, and clinical outcomes for patients with chronic pain. These communications underscore Collegium’s focus on responsible pain management and real-world evidence generation.
Investors following COLL can find regular updates on quarterly financial results, guidance, and non-GAAP metrics such as adjusted EBITDA in the company’s earnings press releases. Additional news covers capital deployment, including share repurchase authorizations and the closing of a syndicated credit facility, as well as participation in healthcare and investor conferences. For those tracking developments in ADHD treatment and opioid-based pain therapies, the Collegium news page offers an organized view of clinical data, commercial progress, and financial disclosures over time.
Collegium Pharmaceutical (Nasdaq: COLL) announced an agreement to acquire BioDelivery Sciences International (BDSI) for $5.60 per share in cash, valuing BDSI at approximately $604 million. This acquisition, expected to close in Q1 2022, aims to enhance Collegium's portfolio in pain management and neurology, with estimated annual synergies of at least $75 million within 12 months. The transaction is anticipated to be accretive to earnings in 2022 and 2023, diversifying revenue sources and accelerating cash flow generation.
Collegium Pharmaceutical, Inc. (Nasdaq: COLL) announced a conference call on February 24, 2022, at 4:30 p.m. ET to discuss its Q4 and full-year 2021 financial results. The call will be accessible via phone at (877) 407-8037 (U.S.) or (201) 689-8037 (International) and will also be available as a live audio webcast on their website. A replay will be posted approximately two hours after the event. Collegium is committed to advancing specialty pharmaceuticals aimed at improving patients' lives.
Collegium Pharmaceutical (Nasdaq: COLL) has reached a settlement framework to resolve 27 opioid-related lawsuits for a maximum payment of $2,750,000. This agreement aims to dismiss all pending cases while ensuring no admission of liability. The settlement, which awaits final approval, reflects the company's commitment to responsible pain management. Executive VP Shirley Kuhlmann expressed satisfaction with the resolution, indicating a focus on future operations free from this litigation burden.
Summary not available.
Collegium Pharmaceutical (Nasdaq: COLL) announced a $25 million Accelerated Share Repurchase (ASR) agreement with Jefferies LLC, part of a larger $100 million share buyback program authorized in August 2021. Upon completion of this ASR, Collegium will have approximately $52.2 million remaining under the buyback authorization. The ASR involves repurchasing around 1,026,694 shares at the $19.48 closing stock price as of November 12, 2021. This move reflects management's confidence in the business and commitment to enhancing shareholder value.
Collegium Pharmaceutical, a leader in responsible pain management, announced its participation in upcoming investor conferences. Management will attend the Jefferies London Healthcare Conference with virtual one-on-one meetings on November 18, 2021, and the Piper Sandler Annual Healthcare Conference featuring a virtual fireside chat on December 1, 2021. The fireside chat will be accessible via the Investor section of their website, with a replay available for 30 days post-event. For more information, visit Collegium's website.
Collegium Pharmaceutical, Inc. (Nasdaq: COLL) announced its participation in two upcoming investor conferences. The Jefferies London Healthcare Conference will host virtual one-on-one meetings on November 18, 2021. Additionally, the Piper Sandler Annual Healthcare Conference 2021 will feature a virtual fireside chat on December 1, 2021. The fireside chat will be webcast, and a replay will be available on the company's Investor section website for 30 days following the event.
Collegium Pharmaceutical, Inc. (Nasdaq: COLL) reported a net income of $8.0 million and adjusted EBITDA of $37.3 million for Q3 2021. The company's Board has authorized a $25 million accelerated share repurchase, part of a broader $100 million initiative. Collegium aims for record full-year revenue and profits, driven by a strong pain management portfolio. Xtampza ER reached a 32.5% market share in ER oxycodone, while the Nucynta franchise exceeded $150 million in revenue. The company updated its 2021 financial guidance, adjusting Xtampza ER expected revenues down to $130-$135 million.
Collegium Pharmaceutical (Nasdaq: COLL) will host a conference call and live webcast on November 4, 2021, at 4:30 p.m. ET to discuss its Q3 2021 financial results and provide a corporate update. Investors can join the call by dialing (877) 407-8037 for U.S. participants or (201) 689-8037 for international callers, referencing the "Collegium Pharmaceutical Q3 2021 Earnings Call." The webcast will be available on the company's website for replay shortly after the event.
Collegium Pharmaceutical (Nasdaq: COLL) presented four poster sessions at the Annual PAINWeek National Conference, emphasizing its commitment to responsible pain management.
The presentations focused on the misuse and abuse of its products, particularly XTAMPZA® ER and Nucynta®, and provided real-world data on their diversion and non-medical use.
These efforts highlight the company's dedication to scientific research and education among healthcare providers, reinforcing its position in the pain management sector.